| Literature DB >> 34059754 |
Suzanne Putney1, Andrew H Theiss1, Nitin K Rajan1, Eszter Deak1, Creighton Buie1, Yvonne Ngo1, Hima Shah1, Victoria Yuan1, Elizabeth Botbol-Ponte1, Adrian Hoyos-Urias1, Oren Knopfmacher1, Catherine A Hogan2, Niaz Banaei2, Meike S Herget3.
Abstract
A key predictor of morbidity and mortality for patients with a bloodstream infection is time to appropriate antimicrobial therapy. Accelerating antimicrobial susceptibility testing from positive blood cultures is therefore key to improving patient outcomes, yet traditional laboratory approaches can require 2-4 days for actionable results. The eQUANT-a novel instrument utilizing electrical biosensors-produces a standardized inoculum equivalent to a 0.5 McFarland directly from positive blood cultures. This proof-of-concept study demonstrates that eQUANT inocula prepared from clinically significant species of Enterobacterales were comparable to 0.5 McF inocula generated from bacterial colonies in both CFU/ml concentration and performance in antimicrobial susceptibility testing, with ≥ 95% essential and categorical agreement for VITEK2 and disk diffusion. The eQUANT, combined with a rapid, direct from positive blood culture identification technique, can allow the clinical laboratory to begin antimicrobial susceptibility testing using a standardized inoculum approximately 2-3 h after a blood culture flags positive. This has the potential to improve clinical practice by accelerating conventional antimicrobial susceptibility testing and the resulting targeted antibiotic therapy.Entities:
Year: 2021 PMID: 34059754 DOI: 10.1038/s41598-021-90830-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379